Computed tomography of sellar and parasellar lesions

What to Do with Incidentally Discovered Pituitary Abnormalities?

Pituitary incidentalomas are discovered in approximately 10% to 40% of brain images. A complete patient history, physical examination, and dedicated pituitary function testing are needed, and subsequent results should lead to appropriate patient management. However, most lesions are asymptomatic pituitary adenomas or Rathke cleft cysts with a benign course. Many lesions can be clinically significant, including prolactinomas or other pituitary adenomas that warrant specific pituitary disease treatment. In other cases, mass effect causing visual compromise or refractory headache indicates a need for surgery. Here, various facets of a complex evaluation and treatment algorithm for pituitary incidentalomas are reviewed.

Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients

Diurnal serum GH patterns were determined in 10 acromegalic patients before treatment, after 3 d continuous s.c. pump infusion and then after 3 d with three equal daily s.c. injections in both instances totalling 100 micrograms/24 h. Subcutaneous injections (33 micrograms) induced impressive suppression of serum GH lasting 3-6 h in eight patients followed by escape to pretreatment values before the next injection. In contrast, continuous infusion resulted in greater and more stable 24 h suppression to the levels reached at the nadir between injections. Suppression of mean 24 h serum GH below 5 ng/ml was achieved by pump treatment in four patients, while two patients had mean values between 5 ng/ml and 10 ng/ml. In four patients occasional or all levels were above 10 ng/ml (24 h average 12.4-102 ng/ml) implying either that adequate suppression by the SMS 201-995, was impossible during the 3 d pump infusion period, or that the dose administered was inadequate. Carbohydrate tolerance was unaffected in either regimen, indicating that reduction in insulin antagonistic hormones balanced inhibition of insulin release. Interestingly, and in contrast to somatostatin, SMS 201-995 did not inhibit TSH release. No untoward effects were observed at the moderate dosage and blood clinical chemistry was unchanged. Fairly constant diurnal serum SMS 201-995 values were obtained during pump infusion, while levels undulated inversely with serum GH during injection treatment. Average diurnal serum somatostatin-C immunoreactivity (all patients) decreased from 496 +/- 129 (mean +/- SD) to 385 +/- 100 ng/ml (P less than 0.003) during pump treatment and did not decrease further during the following 3 d injection treatment (363 +/- 76 ng/ml). The normal adult mean is 179 +/- 40 ng/ml. Computer tomographic (CT) scans of the sellar region were performed in all patients before and after the experimental week. Two patients had extracellular tumours whose size decreased from 8.2 to 4.1 cm3 and from 12.6 to 10.5 cm3. The results demonstrate that superior and stable suppression of GH secretion is obtained during continuous s.c. pump infusion of SMS 201-995.

High-resolution computed tomography in pituitary microadenoma: is seeing believing?

Controversy surrounds the reliability of high-resolution computed tomography (CT) in the identification of functioning microadenomas, especially in patients with hyperprolactinaemia and hypercortisolaemia. We studied 34 such patients: each underwent a high-resolution CT examination of the pituitary gland and each had a trans-sphenoidal exploration. Computed tomography showed 28 focal abnormalities but only 20 of these were confirmed to be due to a tumour at operation. In the other eight the tissue at the site of the radiological abnormality was normal histologically. In a total of 29 patients a tumour was found at operation and confirmed histologically; 20 were at the site of an abnormality shown by CT but in nine a tumour was found in a part of the gland judged to be normal radiologically. In general, good correlation between CT and the surgical findings was found only with tumours more than 6 mm in size. Of the indirect signs of a tumour, such as stalk deviation and a convex upper surface of the gland, only the former showed any correlation with the presence of a tumour. The results show that cautious, even sceptical interpretation of pituitary CT scans is essential and suggest that this investigation is not sufficiently reliable to be used as a routine in the assessment of hyperprolactinaemia or Cushing's syndrome. Computed tomography should be reserved for patients undergoing pituitary surgery, those with an enlarged fossa on plain radiography and those with extreme hormone hypersecretion.